NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37373427/
Despite major progress in mantle cell lymphoma (MCL) therapeutics, MCL remains a deadly disease with a median survival not exceeding four years. No single driver genetic lesion has been described...
Relevance: In this article, we explore in detail the role of NOTCH signaling in MCL biology and the ongoing efforts toward targeted therapeutic interventions.
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory PCNSL Patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37321275/
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients...
Conclusions/Relevance: This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers...
PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37327122/
Mantle cell lymphoma (MCL) is an incurable B cell malignancy, comprising up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival...
PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022) - Clinical and Translational Oncology
Source : https://link.springer.com/article/10.1007/s12094-023-03206-5
Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by...
Conclusions/Relevance: The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.
Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37339585/
The emergence of chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for diffuse large B-cell lymphoma (DLBCL), however, real-world evidence reporting outcomes among older patients treated with...
Conclusions/Relevance: CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low especially in patients age ≥75 and this age group had a lower rate of EFS which illustrates the unmet need for more accessible, effective, and tolerable therapy in older patients, especially in...